A citation-based method for searching scientific literature

Naosuke Nonoguchi, Takashi Ohta, Ji-Eun Oh, Young-Ho Kim, Paul Kleihues, Hiroko Ohgaki. Acta Neuropathol 2013
Times Cited: 145







List of co-cited articles
949 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study.
Song Wu, Peide Huang, Chong Li, Yi Huang, Xianxin Li, Yongqiang Wang, Chao Chen, Zhaojie Lv, Aifa Tang, Xiaojuan Sun,[...]. Eur Urol 2014
66
10

Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions.
Anna E Koopmans, Kimberley Ober, Hendrikus J Dubbink, Dion Paridaens, Nicole C Naus, Stephan Belunek, Bart Krist, Edward Post, Ellen C Zwarthoff, Annelies de Klein,[...]. Invest Ophthalmol Vis Sci 2014
44
15

Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Ren-Chin Wu, Ayse Ayhan, Daichi Maeda, Kyu-Rae Kim, Blaise A Clarke, Patricia Shaw, Michael Herman Chui, Barry Rosen, Ie-Ming Shih, Tian-Li Wang. J Pathol 2014
63
11

Novel anticancer therapeutics targeting telomerase.
Maria Ruden, Neelu Puri. Cancer Treat Rev 2013
191
7

Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Elisabetta Macerola, Barbara Loggini, Riccardo Giannini, Giulia Garavello, Mirella Giordano, Agnese Proietti, Cristina Niccoli, Fulvio Basolo, Gabriella Fontanini. Virchows Arch 2015
39
17

TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Klaus G Griewank, Bastian Schilling, Rajmohan Murali, Nicola Bielefeld, Marion Schwamborn, Antje Sucker, Lisa Zimmer, Uwe Hillen, Jörg Schaller, Thomas Brenn,[...]. Mod Pathol 2014
61
11

Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
A Tallet, J-C Nault, A Renier, I Hysi, F Galateau-Sallé, A Cazes, M-C Copin, P Hofman, P Andujar, F Le Pimpec-Barthes,[...]. Oncogene 2014
50
14

TERT Promoter Mutations and Risk of Recurrence in Meningioma.
Felix Sahm, Daniel Schrimpf, Adriana Olar, Christian Koelsche, David Reuss, Juliane Bissel, Annekathrin Kratz, David Capper, Sebastian Schefzyk, Thomas Hielscher,[...]. J Natl Cancer Inst 2015
154
7

Melanomas of unknown primary frequently harbor TERT-promoter mutations.
Friederike Egberts, Sandra Krüger, Hans M Behrens, Inka Bergner, Giorgios Papaspyrou, Jochen A Werner, Ibrahim Alkatout, Jochen Haag, Axel Hauschild, Christoph Röcken. Melanoma Res 2014
28
25

Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
David E Reuss, Annekathrin Kratz, Felix Sahm, David Capper, Daniel Schrimpf, Christian Koelsche, Volker Hovestadt, Melanie Bewerunge-Hudler, David T W Jones, Jens Schittenhelm,[...]. Acta Neuropathol 2015
157
7

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.
Albert Lai, Samir Kharbanda, Whitney B Pope, Anh Tran, Orestes E Solis, Franklin Peale, William F Forrest, Kanan Pujara, Jose A Carrillo, Ajay Pandita,[...]. J Clin Oncol 2011
295
7

Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
HuyTram N Nguyen, Amy Lie, Tie Li, Reshmi Chowdhury, Fei Liu, Byram Ozer, Bowen Wei, Richard M Green, Benjamin M Ellingson, He-Jing Wang,[...]. Neuro Oncol 2017
45
15

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.
Ethan Cerami, Jianjiong Gao, Ugur Dogrusoz, Benjamin E Gross, Selcuk Onur Sumer, Bülent Arman Aksoy, Anders Jacobsen, Caitlin J Byrne, Michael L Heuer, Erik Larsson,[...]. Cancer Discov 2012
6

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Michael Weller, Ruthild G Weber, Edith Willscher, Vera Riehmer, Bettina Hentschel, Markus Kreuz, Jörg Felsberg, Ulrike Beyer, Henry Löffler-Wirth, Kerstin Kaulich,[...]. Acta Neuropathol 2015
161
6

Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk.
Kyle M Walsh, Veryan Codd, Ivan V Smirnov, Terri Rice, Paul A Decker, Helen M Hansen, Thomas Kollmeyer, Matthew L Kosel, Annette M Molinaro, Lucie S McCoy,[...]. Nat Genet 2014
120
6

Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types.
Nils J Fredriksson, Lars Ny, Jonas A Nilsson, Erik Larsson. Nat Genet 2014
184
6

TERT promoter mutations in cancer development.
Barbara Heidenreich, P Sivaramakrishna Rachakonda, Kari Hemminki, Rajiv Kumar. Curr Opin Genet Dev 2014
144
6

Genetic pathways to glioblastoma: a population-based study.
Hiroko Ohgaki, Pierre Dessen, Benjamin Jourde, Sonja Horstmann, Tomofumi Nishikawa, Pier-Luigi Di Patre, Christoph Burkhard, Danielle Schüler, Nicole M Probst-Hensch, Paulo César Maiorka,[...]. Cancer Res 2004
917
6

Genetic pathways to primary and secondary glioblastoma.
Hiroko Ohgaki, Paul Kleihues. Am J Pathol 2007
880
6

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
M Esteller, J Garcia-Foncillas, E Andion, S N Goodman, O F Hidalgo, V Vanaclocha, S B Baylin, J G Herman. N Engl J Med 2000
6

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
David E Reuss, Felix Sahm, Daniel Schrimpf, Benedikt Wiestler, David Capper, Christian Koelsche, Leonille Schweizer, Andrey Korshunov, David T W Jones, Volker Hovestadt,[...]. Acta Neuropathol 2015
272
6

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
Wolfgang Wick, Michael Platten, Christoph Meisner, Jörg Felsberg, Ghazaleh Tabatabai, Matthias Simon, Guido Nikkhah, Kirsten Papsdorf, Joachim P Steinbach, Michael Sabel,[...]. Lancet Oncol 2012
661
6


Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
Heidi S Phillips, Samir Kharbanda, Ruihuan Chen, William F Forrest, Robert H Soriano, Thomas D Wu, Anjan Misra, Janice M Nigro, Howard Colman, Liliana Soroceanu,[...]. Cancer Cell 2006
6

Clinical and molecular features of Hürthle cell carcinoma of the thyroid.
Ana-Maria Chindris, John D Casler, Victor J Bernet, Michael Rivera, Colleen Thomas, Jennifer M Kachergus, Brian M Necela, Ian D Hay, Sydney A Westphal, Clive S Grant,[...]. J Clin Endocrinol Metab 2015
54
11

Telomerase activation by genomic rearrangements in high-risk neuroblastoma.
Martin Peifer, Falk Hertwig, Frederik Roels, Daniel Dreidax, Moritz Gartlgruber, Roopika Menon, Andrea Krämer, Justin L Roncaioli, Frederik Sand, Johannes M Heuckmann,[...]. Nature 2015
278
6

Genetic Alterations in Gliosarcoma and Giant Cell Glioblastoma.
Ji Eun Oh, Takashi Ohta, Naosuke Nonoguchi, Kaishi Satomi, David Capper, Daniela Pierscianek, Ulrich Sure, Anne Vital, Werner Paulus, Michel Mittelbronn,[...]. Brain Pathol 2016
39
15

TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
Na Wang, Tiantian Liu, Anastasios Sofiadis, C Christofer Juhlin, Jan Zedenius, Anders Höög, Catharina Larsson, Dawei Xu. Cancer 2014
73
8

Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder.
Eric Vail, Xiaoyong Zheng, Ming Zhou, Ximing Yang, John T Fallon, Jonathan I Epstein, Minghao Zhong. Ann Diagn Pathol 2015
22
27

High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression.
Stéphane Goutagny, Jean C Nault, Maxime Mallet, Dominique Henin, Jessica Z Rossi, Michel Kalamarides. Brain Pathol 2014
141
6

TERT promoter mutation is uncommon in acral lentiginous melanoma.
Jau-Yu Liau, Jia-Huei Tsai, Yung-Ming Jeng, Chia-Yu Chu, Kuan-Ting Kuo, Cher-Wei Liang. J Cutan Pathol 2014
30
20

Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
Xiaoguang Shi, Rengyun Liu, Shen Qu, Guangwu Zhu, Justin Bishop, Xiaoli Liu, Hui Sun, Zhongyan Shan, Enhua Wang, Yahong Luo,[...]. J Clin Endocrinol Metab 2015
56
10

Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites.
Katherine A Cheng, Boaz Kurtis, Sabina Babayeva, Jian Zhuge, Irlna Tantchou, Dongming Cai, Rocco J Lafaro, John T Fallon, Minghao Zhong. Ann Diagn Pathol 2015
24
25

Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Jean Charles Nault, Julien Calderaro, Luca Di Tommaso, Charles Balabaud, Elie Serge Zafrani, Paulette Bioulac-Sage, Massimo Roncalli, Jessica Zucman-Rossi. Hepatology 2014
174
6


The Genetic Evolution of Melanoma from Precursor Lesions.
A Hunter Shain, Iwei Yeh, Ivanka Kovalyshyn, Aravindhan Sriharan, Eric Talevich, Alexander Gagnon, Reinhard Dummer, Jeffrey North, Laura Pincus, Beth Ruben,[...]. N Engl J Med 2015
475
6

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wolfgang Wick, Christian Hartmann, Corinna Engel, Mandy Stoffels, Jörg Felsberg, Florian Stockhammer, Michael C Sabel, Susanne Koeppen, Ralf Ketter, Richard Meyermann,[...]. J Clin Oncol 2009
549
6

Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
Xunjun Yang, Xiuchan Guo, Yao Chen, Guorong Chen, Yin Ma, Kate Huang, Yuning Zhang, Qiongya Zhao, Cheryl A Winkler, Ping An,[...]. Oncotarget 2016
20
30


TERT promoter mutations in melanoma survival.
Eduardo Nagore, Barbara Heidenreich, Sívaramakrishna Rachakonda, Zaida Garcia-Casado, Celia Requena, Virtudes Soriano, Christoph Frank, Victor Traves, Esther Quecedo, Josefa Sanjuan-Gimenez,[...]. Int J Cancer 2016
69
8

Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway.
Courtney A Lovejoy, Wendi Li, Steven Reisenweber, Supawat Thongthip, Joanne Bruno, Titia de Lange, Saurav De, John H J Petrini, Patricia A Sung, Maria Jasin,[...]. PLoS Genet 2012
347
6

European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.
Michael Weller, Martin van den Bent, Jörg C Tonn, Roger Stupp, Matthias Preusser, Elizabeth Cohen-Jonathan-Moyal, Roger Henriksson, Emilie Le Rhun, Carmen Balana, Olivier Chinot,[...]. Lancet Oncol 2017
470
6

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Jianjiong Gao, Bülent Arman Aksoy, Ugur Dogrusoz, Gideon Dresdner, Benjamin Gross, S Onur Sumer, Yichao Sun, Anders Jacobsen, Rileen Sinha, Erik Larsson,[...]. Sci Signal 2013
5

Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.
Daniela Lötsch, Bahil Ghanim, Magdalena Laaber, Gabriele Wurm, Serge Weis, Stefan Lenz, Gerald Webersinke, Josef Pichler, Walter Berger, Sabine Spiegl-Kreinecker. Neuro Oncol 2013
48
10

IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.
David E Reuss, Yasin Mamatjan, Daniel Schrimpf, David Capper, Volker Hovestadt, Annekathrin Kratz, Felix Sahm, Christian Koelsche, Andrey Korshunov, Adriana Olar,[...]. Acta Neuropathol 2015
167
5

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Benedikt Wiestler, David Capper, Tim Holland-Letz, Andrey Korshunov, Andreas von Deimling, Stefan Michael Pfister, Michael Platten, Michael Weller, Wolfgang Wick. Acta Neuropathol 2013
198
5

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
Takuya Watanabe, Sumihito Nobusawa, Paul Kleihues, Hiroko Ohgaki. Am J Pathol 2009
663
5

Epithelioid GBMs show a high percentage of BRAF V600E mutation.
Bette Kay Kleinschmidt-DeMasters, Dara L Aisner, Diane K Birks, Nicholas K Foreman. Am J Surg Pathol 2013
154
5

Genome-wide association study identifies five susceptibility loci for glioma.
Sanjay Shete, Fay J Hosking, Lindsay B Robertson, Sara E Dobbins, Marc Sanson, Beatrice Malmer, Matthias Simon, Yannick Marie, Blandine Boisselier, Jean-Yves Delattre,[...]. Nat Genet 2009
588
5

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
Marc Sanson, Yannick Marie, Sophie Paris, Ahmed Idbaih, Julien Laffaire, François Ducray, Soufiane El Hallani, Blandine Boisselier, Karima Mokhtari, Khe Hoang-Xuan,[...]. J Clin Oncol 2009
689
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.